title: Alternative macrophage activation-associated transcripts in T-cell-mediated rejection of mouse kidney allografts.
abstract: Macrophages display two activation states that are considered mutually exclusive: classical macrophage activation (CMA), inducible by IFNG, and alternative macrophage activation (AMA), inducible by IL4 and IL13. CMA is prominent in allograft rejection and AMA is associated with tissue remodeling after injury. We studied expression of AMA markers in mouse kidney allografts and in kidneys with acute tubular necrosis (ATN). In rejecting allografts, unlike interferon gamma (IFNG) effects and T-cell infiltration that developed rapidly and plateaued by day 7, AMA transcripts (Arg1, Mrc1, Mmp12 and Ear1) rose progressively as tubulitis and parenchymal deterioration developed at days 21 and 42, despite persistent IFNG effects. AMA in allografts was associated with transcripts for AMA inducers IL4, IL13 and inhibin A, but also occurred when hosts lacked IL4/IL13 receptors, suggesting a role for inhibin A. Kidneys with ATN injured by ischemia/reperfusion also had increased expression of AMA markers and inhibin A. Thus kidneys undergoing T-cell-mediated rejection progressively acquire macrophages with alternative activation phenotype despite strong local IFNG effects, independent of IL4 and IL13. Although the mechanisms and causal relationships remain to be determined, high AMA transcript levels in rejecting allografts are strongly associated with and may be a consequence of parenchymal deterioration similar to ATN.
authors.affiliation: Alberta Transplant Applied Genomics Centre, Division of Nephrology and Transplant Immunology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. konrad@ualberta.ca
authors.forename: K S
authors.initials: KS
authors.lastname: Famulski
authors.forename: D
authors.initials: D
authors.lastname: Kayser
authors.forename: G
authors.initials: G
authors.lastname: Einecke
authors.forename: K
authors.initials: K
authors.lastname: Allanach
authors.forename: D
authors.initials: D
authors.lastname: Badr
authors.forename: J
authors.initials: J
authors.lastname: Venner
authors.forename: B
authors.initials: B
authors.lastname: Sis
authors.forename: P F
authors.initials: PF
authors.lastname: Halloran
mesh_terms: D028341:Activins / Q000378:metabolism; D000818:Animals; D006084:Graft Rejection; D007265:Inhibins / Q000378:metabolism; D018793:Interleukin-13 / Q000378:metabolism; D015847:Interleukin-4 / Q000378:metabolism; D016030:Kidney Transplantation / Q000379:methods*; D008262:Macrophage Activation; D008264:Macrophages / Q000166:cytology* / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008808:Mice, Inbred CBA; D008954:Models, Biological; D015427:Reperfusion Injury / Q000378:metabolism; D013601:T-Lymphocytes / Q000166:cytology* / Q000378:metabolism
chemical_list: D018793:Interleukin-13; C422362:inhibin A; D028341:Activins; D015847:Interleukin-4; D007265:Inhibins